Specjalistyczny Szpital Im. Dra Alfreda Sokolowskiego
- Address
- lock Available on a paid plan
Specjalistyczny Szpital Im. Dra Alfreda Sokolowskiego
The Dr. Alfred Sokolowski Specialist Hospital is a prominent clinical research center with extensive expertise in hematologic malignancies and oncology. The facility demonstrates particular strength in conducting advanced Phase 3 trials for blood cancers and solid tumors, with a focus on novel immunotherapeutic approaches and combination treatment strategies.
- Multiple Myeloma and Plasma Cell Disorders - investigating innovative combinations including teclistamab, iberdomide, and belantamab mafodotin regimens
- Myeloproliferative Neoplasms and Myelodysplastic Syndromes - evaluating targeted therapies for myelofibrosis, polycythemia vera, and higher-risk MDS
- Lymphoid Malignancies - conducting trials in chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma
- Solid Tumor Oncology - assessing novel immunotherapy combinations for non-small cell lung cancer and triple-negative breast cancer
The center's research portfolio reflects a comprehensive approach to cancer care, ranging from first-line treatments in newly diagnosed patients to advanced therapies for relapsed or refractory disease. Their participation in cardiovascular studies, including post-myocardial infarction heart failure management, further demonstrates their commitment to multidisciplinary clinical research and improving patient outcomes across multiple therapeutic areas.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 5 therapeutic areas and 15 of 102 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 95 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 19 by active trials.
- 1Regeneron Pharmaceuticals Inc.3active
lock +18 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Regeneron Pharmaceuticals Inc.5trials
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Specjalistyczny Szpital Im. Dra Alfreda Sokolowskiego
lock Showing 1 of 43 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-003) | Merck Sharp & Dohme LLC | Phase IV | Recruiting | Jun 2022 | — |
IMP list
lock Showing 1 of 102 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Rituximab | 8 | Unknown | 2020-01-20 | 2025-12-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.